In accordance with the previous observation that overexpression of ZNF217 decreases doxorubicin-induced cell death in cervical (HeLa) and breast (HBL100) cancer cell lines [14], the two ZNF217-overexpressing MDA-MB-231 cell lines studied also displayed a ~2.3-fold relative resistance to the topoisomerase inhibitor doxorubicin (data not shown). This evidence concerns the gene ZNF217 and cancer.